PHASE 8 DELIVERABLE
IND-Ready CMC Package (Module 3)
AMX-B01 — Geniposide-Enriched Purified Botanical API
Document Code: SCF-AMMONEX-HE-AMXB01-P8-0001
Trigger Executed: CMC IND
Development Stage: Chemistry, Manufacturing & Controls (CMC)
Regulatory Purpose:
Establish a complete FDA-aligned Module 3 CMC package sufficient to support IND submission, GMP manufacturing, clinical material production, and First-In-Human (FIH) studies.
1.0 CMC EXECUTIVE SUMMARY
Product
AMX-B01
API Type
Purified Botanical-Derived Active Pharmaceutical Ingredient
Source
Genipa americana
Marker Compound
Geniposide
Dosage Form
Oral Capsule
Development Objective
Produce a reproducible, stable, pharmaceutical-grade geniposide API suitable for clinical development.
2.0 MODULE 3 CMC ARCHITECTURE
3.2.S Drug Substance
Required Sections
Section | Content |
S.1 | General Information |
S.2 | Manufacture |
S.3 | Characterization |
S.4 | Control of Drug Substance |
S.5 | Reference Standards |
S.6 | Container Closure System |
S.7 | Stability |
3.2.P Drug Product
Required Sections
Section | Content |
P.1 | Description & Composition |
P.2 | Pharmaceutical Development |
P.3 | Manufacture |
P.4 | Control of Excipients |
P.5 | Drug Product Specifications |
P.6 | Reference Standards |
P.7 | Container Closure |
P.8 | Stability |
3.0 DRUG SUBSTANCE PACKAGE
API Name
AMX-B01
Description
Geniposide-Enriched Purified Botanical API
Source Material
Botanical Species
Genipa americana
Plant Part
Immature Fruit / Fruit Pulp
Source Qualification
- Botanical authentication
- DNA verification
- Chemical fingerprint verification
- Traceability documentation
Established during Phase 1 source qualification.
4.0 MANUFACTURING PROCESS DESCRIPTION
Process Flow
Authenticated Botanical Material
↓
Cleaning
↓
Drying
↓
Milling
↓
Hydroethanolic Extraction
↓
Filtration
↓
Concentration
↓
Resin Enrichment
↓
Preparative Chromatography
↓
Purification
↓
Drying
↓
API Packaging
↓
AMX-B01 Drug Substance
Critical Process Controls
CPP-1
Raw Material Identity
Acceptance
Pass authentication program
CPP-2
Extraction Solvent Ratio
Target
50% Ethanol / 50% Water
CPP-3
Extraction Temperature
Target
40–60°C
CPP-4
Chromatographic Purification
Target
≥95% Geniposide
5.0 DRUG SUBSTANCE SPECIFICATIONS
AMX-B01 API Release Specification
Test | Specification |
Description | Conforms |
Identification (HPLC) | Pass |
Identification (LC-MS) | Pass |
Assay (Geniposide) | ≥95.0% |
Water Content | ≤5.0% |
Residual Solvents | Within ICH Limits |
Heavy Metals | Within Limits |
Total Microbial Count | Within Limits |
Related Substances | Defined Limits |
6.0 ANALYTICAL METHODS PACKAGE
Identity Methods
Method 1
HPLC Fingerprint
Purpose:
Identity confirmation
Method 2
LC-MS
Purpose:
Molecular confirmation
Method 3
NMR
Purpose:
Structural confirmation
Quantitative Method
HPLC Assay
Primary release assay.
Impurity Method
Stability-Indicating HPLC
Purpose:
Related substances and degradation products.
7.0 ANALYTICAL VALIDATION PLAN
Validation Parameters
Parameter | Requirement |
Specificity | Required |
Accuracy | Required |
Precision | Required |
Linearity | Required |
Range | Required |
Robustness | Required |
Validation Timing
IND Support
Phase-appropriate validation
Late Development
Full ICH validation
8.0 REFERENCE STANDARD PROGRAM
Primary Standard
Geniposide RS-01
Qualification Package
- HPLC
- LC-MS
- NMR
- Water content
- Purity determination
Acceptance
≥98% purity
9.0 DRUG PRODUCT DEVELOPMENT
Formulation Candidate
AMX-B01-F2
Preferred Development Formulation
Dosage Form
Capsule
Composition
Component | Function |
AMX-B01 API | Active |
Phospholipid Complex | Absorption Enhancement |
Microcrystalline Cellulose | Filler |
Magnesium Stearate | Lubricant |
Capsule Shell | Delivery Vehicle |
10.0 GMP MANUFACTURING STRATEGY
Manufacturing Phase
Discovery
Pilot scale
IND
GMP clinical manufacturing
Phase I
Qualified GMP production
Required Systems
- Batch records
- Change control
- Deviation management
- Supplier qualification
- CAPA program
11.0 BOTANICAL CONTROL STRATEGY
Botanical Raw Material Controls
Identity
- Morphology
- DNA
- HPLC fingerprint
Quality
- Heavy metals
- Pesticides
- Microbial burden
Traceability
- Harvest records
- Geographic origin
- Chain of custody
12.0 STABILITY PROGRAM
Drug Substance Stability
Accelerated
40°C / 75% RH
Duration:
6 months
Long-Term
25°C / 60% RH
Duration:
24 months
Drug Product Stability
Evaluate
- Assay
- Impurities
- Dissolution
- Moisture
- Appearance
13.0 CONTAINER CLOSURE SYSTEM
Drug Substance
Packaging
- Double polyethylene bags
- HDPE container
Drug Product
Packaging
- HDPE bottle
- Desiccant system
- Child-resistant closure
14.0 CMC RISK ASSESSMENT
Risk | Priority | Mitigation |
Botanical variability | High | Source qualification |
Marker fluctuation | High | Geniposide release specification |
Stability loss | Moderate | Stability program |
Impurity formation | Moderate | Stability-indicating methods |
Supply interruption | Moderate | Multi-source strategy |
15.0 MODULE 3 IND READINESS CHECKLIST
Drug Substance
✓ Identity established
✓ Manufacturing process defined
✓ Specifications established
✓ Analytical methods established
✓ Reference standards established
Drug Product
✓ Formulation selected
✓ Specifications defined
✓ Stability program initiated
✓ Packaging defined
Botanical Controls
✓ Authentication system established
✓ Traceability system established
✓ Quality control system established
16.0 PHASE 8 DECISION GATE
Advancement Criteria
✓ IND-supportive CMC package completed
✓ Drug substance specifications established
✓ Drug product specifications established
✓ Analytical methods qualified
✓ Stability program initiated
✓ GMP strategy defined
Status
ADVANCE TO PHASE 9
Required Next Trigger
PRE-IND
Phase 9 will generate:
- FDA Pre-IND briefing package
- Regulatory strategy dossier
- Nonclinical summary package
- CMC summary package
- Clinical development rationale
- FDA interaction strategy
- IND gap analysis
- Pre-IND meeting question package
MASTER REGISTRY INDEX
SCF-AMMONEX-HE-AMXB01-P8-0001 — IND-Ready CMC Package
SCF-AMMONEX-HE-AMXB01-M3-0002 — Module 3 CMC Blueprint
SCF-AMMONEX-HE-AMXB01-DS-0003 — Drug Substance Package
SCF-AMMONEX-HE-AMXB01-DP-0004 — Drug Product Package
SCF-AMMONEX-HE-AMXB01-GMP-0005 — GMP Manufacturing Strategy
SCF-AMMONEX-HE-AMXB01-STAB-0006 — Stability Program
SCF-AMMONEX-HE-AMXB01-P9-0007 — Pre-IND Development Initiation